WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206078
Description: Teroxirone, also known as Triglycidyl Isocyanurate and Tris(2,3-epoxypropyl) Isocyanurate, is a triazene triepoxide with antineoplastic activity. Teroxine alkylates and cross-links DNA, thereby inhibiting DNA replication.
MedKoo Cat#: 206078
Chemical Formula: C12H15N3O6
Exact Mass: 297.09609
Molecular Weight: 297.26
Elemental Analysis: C, 48.48; H, 5.09; N, 14.14; O, 32.29
Synonym: Teroxirone; Henkels Compound; alphaTGI; alpha-triglycidyl isocyanurate; Triglycidyl Isocyanurate; Tris(2,3-epoxypropyl) Isocyanurate.
IUPAC/Chemical Name: 1,3,5-tris(oxiran-2-ylmethyl)-1,3,5-triazinane-2,4,6-trione
SMILES Code: O=C(N(CC1OC1)C(N2CC3OC3)=O)N(CC4OC4)C2=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 297.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Wang JP, Lin KH, Liu CY, Yu YC, Wu PT, Chiu CC, Su CL, Chen KM, Fang K. Teroxirone inhibited growth of human non-small cell lung cancer cells by activating p53. Toxicol Appl Pharmacol. 2013 Aug 15;273(1):110-120. doi: 10.1016/j.taap.2013.08.007. [Epub ahead of print] PubMed PMID: 23954467.
2: Rubin J, Kovach JS, Ames MM, Moertel CG, Creagan ET, O'Connell MJ. Phase I study of two schedules of teroxirone. Cancer Treat Rep. 1987 May;71(5):489-92. PubMed PMID: 3567975.
3: Ames MM, Kovach JS, Rubin J. Pharmacological characterization of teroxirone, a triepoxide antitumor agent, in rats, rabbits, and humans. Cancer Res. 1984 Sep;44(9):4151-6. PubMed PMID: 6744326.
4: Neidhart JA, Derocher D, Grever MR, Kraut EH, Malspeis L. Phase I trial of teroxirone. Cancer Treat Rep. 1984 Sep;68(9):1115-9. PubMed PMID: 6478450